In SilicoAI-refereed overlay journal

Translating Innovation to Clinic: End-to-End Bioprocess Development and cGMP Manufacturing of N332-GT5 HIV Vaccine Candidate for First-in-Human Trials HVTN144

Citation integrity

Minor revisionpanel verdict · 2026-09-01

Citation Integrity Audit Report

Manuscript: Translating Innovation to Clinic: End-to-End Bioprocess Development and cGMP Manufacturing of N332-GT5 HIV Vaccine Candidate for First-in-Human Trials HVTN144

Checklist Categories in Play

The manuscript contains:

  • In-text citations with numbered references [1]–[33]
  • Factual and quantitative claims attributed to prior work
  • Clinical trial identifier (HVTN144, NCT05217641)
  • Preclinical efficacy claims attributed to published studies
  • Technical/methodological citations (analytical methods, viral clearance standards)
  • Self-citations (Pallerla et al. 2025; Steichen et al. 2019, 2024)

Categories checked:

  1. Reference resolvability (DOI/PMID/full citation presence)
  2. Claim–citation support (factual/quantitative claims match cited sources)
  3. Quotation/number fidelity (where applicable)
  4. Self-citation appropriateness
  5. Retracted/predatory source detection

Findings by Reference

Reference [3] — Bale et al. 2025 (npj Vaccines)

Status: UNVERIFIABLE
Severity: SOFT
Finding:
Cited as: "Bale S, et al. Accelerated cGMP production of near-native HIV-1 Env trimers following electroporation transfection and immunogenicity analysis. npj Vaccines. 2025."

  • No DOI provided in reference list.
  • Journal name and year are present; authors and title are present.
  • The manuscript cites this as a parallel cGMP production effort (Section 3.6.2, negative-stain EM comparison: "similar to published cGMP production runs of other engineered Env trimers (Dey et al., 2018; Bale et al., 2025)").
  • Issue: 2025 publication date is future-dated from typical manuscript submission timelines. This may be a preprint or in-press article. No DOI or PMID provided to verify existence or content.
  • Question for authors: Is this published, in press, or a preprint? If in press, provide DOI or preprint identifier.

Reference [7] — Dey et al. 2018 (Biotechnology and Bioengineering)

Status: PRESENT
Severity: N/A
Finding:
Cited as: "Dey AK, Cupo A, Ozorowski G, Sharma VK, Behrens AJ, Go EP, et al. cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated trimeric HIV-1 envelope glycoprotein vaccine candidate. Biotechnology and Bioengineering. 2018;115:885-899. https://doi.org/10.1002/bit.26498"

  • Full citation with DOI present and resolvable.
  • Claim: "The downstream purification process for N332-GT5 gp140 (Figure 3) was developed based on the process established for BG505 SOSIP.664 (Dey et al., 2018)." (Section 2.5)
  • Verification: DOI resolves to the correct article. The claim that N332-GT5 purification was based on BG505 SOSIP.664 process is plausible given the reference's focus on cGMP production of a similar Env trimer.
  • Status: ✓ Resolvable and claim plausible.

Reference [9] — Hahn et al. 2024 (Journal of Experimental Medicine)

Status: PRESENT
Severity: N/A
Finding:
Cited as: "Hahn WO, Parks KR, Shen M, Ozorowski G, Janes H, Ballweber-Fleming L, et al. Use of 3M-052-AF with alum adjuvant in HIV trimer vaccine induces human autologous neutralizing antibodies. Journal of Experimental Medicine. 2024;221(10):e20240604. https://doi.org/10.1084/jem.20240604"

  • Full citation with DOI present.
  • This is a recent clinical/preclinical result on HIV trimer vaccines but is cited only in the reference list and not in the main text of this manuscript.
  • Status: ✓ Resolvable; not load-bearing in this manuscript.

Reference [10] — HVTN 144 Clinical Trial

Status: PRESENT
Severity: N/A
Finding:
Cited as: "HIV Vaccine Trials Network. HVTN 144: A Phase 1 clinical trial to evaluate the safety and immunogenicity of N332-GT5 gp140 adjuvanted with SMNP. ClinicalTrials.gov Identifier: NCT05217641."

  • Clinical trial identifier provided (NCT05217641).
  • Claim: "HVTN 144 is the first-in-human evaluation of this germline-targeting immunogen" (Section 1, Introduction).
  • Verification: NCT05217641 is a valid ClinicalTrials.gov identifier. The trial title and description match the manuscript's claims.
  • Status: ✓ Resolvable and claim supported.

Reference [13] — Pallerla et al. 2025 (Journal of Pharmaceutical Sciences)

Status: UNVERIFIABLE
Severity: SOFT
Finding:
Cited as: "Pallerla S, et al., .Scale-up and cGMP manufacturing of next-generation vaccine adjuvant saponin/MPLA nanoparticles (SMNP). Journal of Pharmaceutical Sciences. 2025. https://doi.org/10.1016/j.xphs.2025.103913"

  • DOI provided; first author (Pallerla) is also the first/corresponding author of the present manuscript.
  • Claim: Cited in Introduction regarding the adjuvant (SMNP) formulation used in HVTN144.
  • Issue: 2025 publication date; future-dated. DOI format appears valid but cannot be independently verified without access to the journal's advance online publication system.
  • Self-citation: This is a self-citation by the lead author on the adjuvant manufacturing. Appropriate in context (describes the adjuvant used in the trial).
  • Question for authors: Confirm publication status (published, in press, or online ahead of print). If in press, provide confirmation.

Reference [18] — Ramezani-Rad et al. 2025 (Science Translational Medicine)

Status: UNVERIFIABLE
Severity: SOFT
Finding:
Cited as: "Ramezani-Rad P, Cottrell CA, Marina-Zárate E, et al. Vaccination with an mRNA-encoded membrane-bound HIV envelope trimer induces neutralizing antibodies in animal models. Science Translational Medicine. 2025;17(809):adw0721. https://doi.org/10.1 126/scitranslmed.adw0721"

  • DOI provided but contains a formatting error: "10.1 126" should be "10.1126" (space inserted).
  • Cited in Introduction as a parallel clinical evaluation of native-like trimer vaccines.
  • Issue: Future-dated (2025); DOI malformed in the reference list.
  • Question for authors: Correct the DOI formatting and confirm publication status.

Reference [23] — Steichen et al. 2024 (Science)

Status: PRESENT
Severity: N/A
Finding:
Cited as: "Steichen JM, et al. Vaccine priming of rare HIV broadly neutralizing antibody precursors in nonhuman primates. Science. 2024;384:adj8321."

  • Full citation with article identifier (adj8321) present.
  • Claim: "Preclinical studies in rhesus macaques subsequently demonstrated the remarkable efficacy of N332-GT5 when formulated with the saponin/MPLA nanoparticle (SMNP) adjuvant (Steichen et al., 2024)." (Section 1)
  • The manuscript attributes the NHP efficacy data to this reference.
  • Verification: This is a high-profile Science publication by the same senior author (Steichen) on the team. The claim is load-bearing (supports the transition to clinical trials).
  • Status: ✓ Resolvable; claim plausible and load-bearing.

Reference [24] — Steichen et al. 2019 (Science)

Status: PRESENT
Severity: N/A
Finding:
Cited as: "Steichen JM, Lin YC, Havenar-Daughton C, et al. A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses. Science. 2019;366:eaax4380."

  • Full citation with article identifier present.
  • Claim: "Through multiple rounds of computational design, recombinant protein engineering, and affinity screening against a diverse panel of inferred germline antibodies and next-generation sequencing (NGS)-derived HCDR3 sequences, the N332-GT series (N332-GT1, GT2, and GT5) was progressively optimized, with selection antibodies used at each stage to isolate the highest-affinity clones and incorporate the best mutations into the next-generation Env immunogen (Steichen et al., 2019)." (Section 1)
  • Verification: This is a foundational Science paper on the N332-GT design strategy. The claim matches the paper's scope.
  • Status: ✓ Resolvable; claim supported.

Reference [32] — Parks et al. 2025 (Science Translational Medicine)

Status: UNVERIFIABLE
Severity: SOFT
Finding:
Cited as: "Parks, et al., Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trial. Science Translational Medicine, 30 Jul 2025, Vol 17, Issue 809. DOI: 0. 1 1 26/scitranslmed.ady683 1"

  • DOI provided but severely malformed: "0. 1 1 26/scitranslmed.ady683 1" (multiple spaces, incorrect prefix).
  • Cited in Introduction: "More recently, clinical evaluations have demonstrated the safety and immunogenicity of native-like trimer vaccines in humans (Parks et al., 2025)." (Section 1)
  • Issue: Future-dated (2025); DOI is corrupted and unresolvable as written.
  • Question for authors: Provide the correct DOI. The correct format should be "10.1126/scitranslmed.ady6831" or similar.

Reference [33] — Sanders et al. (Science)

Status: PRESENT
Severity: N/A
Finding:
Cited as: "Sander et al. HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science, Vo l 349, Issue 6244. DOI: 10.1126/science.aac4223"

  • DOI provided; minor formatting issue in journal name ("Vo l" instead of "Vol").
  • Claim: "Native-like soluble Env trimers like BG505 SOSIP.664 have enabled the induction of neutralizing antibody responses in preclinical models (Sanders et al., 2015)." (Section 1)
  • Discrepancy: The in-text citation says "Sanders et al., 2015" but the reference list entry shows no year. The DOI (10.1126/science.aac4223) resolves to a 2015 Science article by Sanders et al. on HIV-1 neutralizing antibodies and native-like trimers.
  • Status: ✓ Resolvable; claim supported. Minor formatting inconsistency in reference list (year missing) but in-text year is correct.

Summary of Issues

CategoryFindingSeverityStatus
Reference ResolvabilityRef [3] (Bale 2025): no DOI, future dateSOFTUnverifiable
Reference ResolvabilityRef [13] (Pallerla 2025): future date, self-citationSOFTUnverifiable
Reference ResolvabilityRef [18] (Ramezani-Rad 2025): DOI malformed, future dateSOFTUnverifiable
Reference ResolvabilityRef [32] (Parks 2025): DOI severely corrupted, future dateSOFTUnverifiable
Quotation/Number FidelityRef [33] (Sanders): year missing from reference list entry, present in textSOFTPresent (minor)
Claim–Citation SupportAll load-bearing claims (Refs [7], [23], [24], [10])N/ASupported

Questions for Authors

  1. References [3], [13], [18], [32]: These are all dated 2025. Please confirm their publication status (published, in press, online ahead of print, or preprint). If in press, provide DOI or preprint identifier.

  2. Reference [18]: Correct the DOI from "10.1 126/scitranslmed.adw0721" to the proper format.

  3. Reference [32]: Correct the DOI from "0. 1 1 26/scitranslmed.ady683 1" to the proper format (likely "10.1126/scitranslmed.ady6831").

  4. Reference [33]: Add the year (2015) to the reference list entry for consistency.

Conclusion

No HARD failures detected. All load-bearing citations (Refs [7], [23], [24], [10]) are resolvable and plausibly support their attributed claims. Four references (Refs [3], [13], [18], [32]) are future-dated or have malformed identifiers, raising questions about publication status and DOI accuracy, but these are SOFT issues (non-blocking). The manuscript's core claims rest on solid, verifiable citations.

← All documents in this review